ArticleClinical and vaccine immunology : CVI2011
Analysis of antibody responses to Mycobacterium leprae phenolic glycolipid I, lipoarabinomannan, and recombinant proteins to define disease subtype-specific antigenic profiles in leprosy.
Article in Clinical and vaccine immunology : CVI, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Comparative analysis of the leprosy detection rate regarding its clinical spectrum through PCR using theFrontiers in microbiology · 2024Pooled it
- Longitudinal assessment of anti-PGL-I serology in contacts of leprosy patients in Bangladesh.PLoS neglected tropical diseases · 2017Trial
- Serum geoepidemiology of leprosy biomarkers in a city-wide COVID-19 survey in Brazil.BMC infectious diseases · 2026Article
- ELISA-R: an R-based method for robust ELISA data analysis.Frontiers in immunology · 2024Article
- Leprosy among children in an area without primary health care coverage in Caratateua Island, Brazilian Amazon.Frontiers in medicine · 2023Article
- Pathogenicity and virulence ofVirulence · 2022Review
- ELISA Test Based on the Phenolic Glycolipid-I (PGL-I) ofPathogens (Basel, Switzerland) · 2022Article
- In search of biomarkers for leprosy by unraveling the host immune response to Mycobacterium leprae.Immunological reviews · 2021Review
- Synthetic Phenolic Glycolipids for Application in Diagnostic Tests for Leprosy.Chembiochem : a European journal of chemical biology · 2021Article
- Insights intoProteomes · 2021Review
- Drug Delivery Systems on Leprosy Therapy: Moving Towards Eradication?Pharmaceutics · 2020Review
- Leprosy transmission in endemic and non-endemic areas based on the profile of antibody response of PGL-1 and PCR detection ofInfectious disease reports · 2020Article
- Evaluation of antibody detection against the NDO-BSA, LID-1 and NDO-LID antigens as confirmatory tests to support the diagnosis of leprosy in Yunnan province, southwest China.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2020Article
- Recombinant polypeptide of Mycobacterium leprae as a potential tool for serological detection of leprosy.AMB Express · 2019Article
- Host immune responses induced by specific Mycobacterium leprae antigens in an overnight whole-blood assay correlate with the diagnosis of paucibacillary leprosy patients in China.PLoS neglected tropical diseases · 2019Article
- Glycopeptides and -Mimetics to Detect, Monitor and Inhibit Bacterial and Viral Infections: Recent Advances and Perspectives.Molecules (Basel, Switzerland) · 2019Review
- Evaluation of Immunodiagnostic Tests for Leprosy in Brazil, China and Ethiopia.Scientific reports · 2018Article
- Vaccines for Leprosy and Tuberculosis: Opportunities for Shared Research, Development, and Application.Frontiers in immunology · 2018Review
- Accuracy of Enzyme-Linked Immunosorbent Assays (ELISAs) in Detecting Antibodies againstThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2018Review
- Field-friendly serological tests for determination of M. leprae-specific antibodies.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 2 countries.
Funding
Abstract
A simple serodiagnostic test based on the Mycobacterium leprae-specific phenolic glycolipid I(PGL-I), for individuals with leprosy is nearly universally positive in leprosy patients with high bacillary loads but cannot be used as a stand-alone diagnostic test for the entire spectrum of the disease process. For patients with early infection with no detectable acid-fast bacilli in lesions or with low or no antibody titer to PGL-I, as in those at the tuberculoid end of the disease spectrum, this diagnostic approach has limited usefulness. To identify additional M. leprae antigens that might enhance the serological detection of these individuals, we have examined the reactivity patterns of patient sera to PGL-I, lipoarabinomannan (LAM), and six recombinant M. leprae proteins (ML1877, ML0841, ML2028, ML2038, ML0380, and ML0050) by Western blot analysis and enzyme-linked immunosorbent assay (ELISA). Overall, the responses to ML2028 (Ag85B) and ML2038 (bacterioferritin) were consistently high in both multibacillary and paucibacillary groups and weak or absent in endemic controls, while responses to other antigens showed considerable variability, from strongly positive to completely negative. This analysis has given a clearer understanding of some of the differences in the antibody responses between individuals at opposite ends of the disease spectrum, as well as illustrating the heterogeneity of antibody responses toward protein, carbohydrate, and glycolipid antigens within a clinical group. Correlating these response patterns with a particular disease state could allow for a more critical assessment of the form of disease within the leprosy spectrum and could lead to better patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.